Category Archives: Cell Therapy

Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Technologies Market Report - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Cell Therapy Technologies Market is Projected to Reach USD 5.6 Billion by 2025 from USD 2.8 Billion in 2020, at a CAGR of 14.4% from 2020 to 2025.

The growth of this market is driven by the rising government investments in cell-based research, increasing incidence of chronic and infectious diseases, a large number of oncology-related cell therapy clinical trials, and increasing GMP certifications for cell therapy production facilities. Also, the emergence of iPSCs as an alternative to ESCs and increased focus on personalized medicine to offer an opportunity for the growth of the market during the forecast period.

Consumables are expected to hold the largest share of the cell therapy technologies market, by product in 2020.

On the basis of product, the market is segmented into consumables, equipment, and systems & software. The consumables segment accounted for the largest share of the cell therapy technologies market in 2019. Factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research are contributing to the growth of the cell therapy consumables market.

T-cells are expected to hold the largest share of the cell therapy technologies market, in 2020.

On the basis of cell type, the market is segmented into, T-cells, stem cells, and other cells. In 2019, T-cells accounted for the largest share of the cell therapy technologies market. Favorable government initiatives and the increasing demand for T-cell therapies are the key factors driving the growth of this segment.

Cell processing is expected to hold the largest share of the cell therapy technologies market in 2020.

On the basis of process, the market is segmented into cell processing, cell preservation, distribution and handling, and process monitoring and quality control. The cell processing segment dominated the market in 2019. This segment is expected to grow at the highest CAGR during the forecast period. The cell processing stage makes the highest use of cell therapy instruments and media, especially during culture media processing. This is the major factor responsible for the large share and high growth of this segment.

Story continues

Biopharmaceutical & biotechnology companies and CROs segment commanded the largest share of the cell therapy technologies market in 2020

By end-user, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies and CROs and research institutes and cell banks. Biopharmaceutical & biotechnology companies and CROs dominate the market and are expected to grow at the highest CAGR. The large share of this regional segment can primarily be attributed to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.

North America commanded the largest share of the cell therapy technologies market in 2020.

On the basis of region, the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2019, North America commanded the largest share of the cell therapy technologies market. The large share of this market segment can be attributed to the increasing incidence of CVD, increasing healthcare expenditure, growing disposable income, growing healthcare awareness, and the availability of technologically advanced devices in the region.

Some of the major players operating in this market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany) and Danaher Corporation (US).

Frequently Asked Questions:

What are the growth opportunities in the cell therapy technologies market across major regions in the future?

Which type of cells are expected to hold the largest share in the cell therapy technologies market?

What are the various cell therapy technologies product types and their respective market shares in the overall market?

Which region has a well-developed cell therapy technologies market?

What is the impact of COVID-19 on cell therapy technologies market?

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Cell Therapy Technologies Market, by Product

7 Cell Therapy Technologies Market, by Process

8 Cell Therapy Technologies Market, by Cell Type

9 Cell Therapy Technologies Market, by End-user

10 Cell Therapy Technologies Market, by Region

11 Competitive Landscape & Company Profiles

Avantor, Inc.

Becton, Dickinson and Company

Bio-Techne Corporation

Cellgenix GmbH

Corning Incorporated

Danaher Corporation

Fresenius Medical Care AG & Co. KGaA

Fujifilm Irvine Scientific

Hemasoft

Ixcells Biotechnology

L7 Informatics

Lonza Group

Mak-System

Maxcyte

Merck KGaA

Miltenyi Biotec GmbH

Organabio, LLC

Roosterbio

Sartorius Ag

Sirion Biotech GmbH

Stemcell Technologies

Terumo Bct, Inc.

Thermo Fisher Scientific

Werum IT Solutions GmbH

Wilson Wolf Corporation

For more information about this report visit https://www.researchandmarkets.com/r/xonbsl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Originally published February 1, 2021, 8:33 AM

Continue reading here:
$5.6 Billion Cell Therapy Technologies Markets, 2025 with Thermo Fisher Scientific, Merck KGaA, and Danaher Dominating - Yahoo Finance

COLOGNE, GERMANY and PHILADELPHIA, PA / ACCESSWIRE / February 2, 2021 / CEVEC Pharma GmbH (CEVEC) and Carisma Therapeutics Inc.(CARISMA) today announced the signing of an agreement which grants CARISMA a clinical and commercial license for CEVEC's proprietary CAP(R) Technology for the manufacturing of RCA-free adenovirus vectors for use in anti-tumor cell therapy.

The deal will allow CARISMA to use the technology across their portfolio of chimeric antigen receptor macrophages (CAR-M) immunotherapies in cancer indications. No further details of the agreement were disclosed.

"We are excited to have signed this new license agreement with CARISMA, enabling them to use our CAP(R) Technology to safely manufacture adenoviral vectors for their engineered monocyte and macrophage platforms," said Dr. Nicole Faust, CEO of CEVEC. "Having a platform capable of producing RCA-free adenoviral vectors is crucially important for adenovirus-based therapies. We look forward to strengthening our successful collaboration with CARISMA over the next years, by providing a key element for their innovative cell therapy concept, helping them to bring the power of cellular immunotherapy to potentially treat patients with hard-to-treat cancers."

"This collaboration with CEVEC is a key proof point to CARISMA's commitment to tapping the potential of CAR-Ms as a therapeutic pathway. We are eager to work with companies that match our dedication to patients and the field of immunotherapy," said Steven Kelly, President and Chief Executive Officer at CARISMA Therapeutics. "We look forward to applying CEVEC's CAP(R) Technology to the continued development of our CAR-M platform."

About CAP(R) Technology - Cell lines specifically designed for vector production

CEVEC's CAP(R) cell line is based on an engineered human suspension cell line of non-tumor origin, derived from human amniocytes. CAP(R) cells can be grown in all formats and all sizes of bioreactors providing a robust, fully scalable production platform for the manufacturing of viral vectors from research grade and smaller amounts up to industrial volumes. The CAP(R) cell line is fully documented and reviewed by regulatory authorities. Since 2016, a Biologics Master File (BMP) is available for reference with the US FDA. GMP Master Cell Banks are available and ready for licensing.

About RCA-free adenoviral vectors - A major challenge in vector manufacturing

Recombinant adenoviral vectors (AdV) were among the first vectors for gene therapy purposes and have become an important vehicle for vaccines and human gene therapies. Today, many cell lines used for production of AdV generate certain levels of replication-competent adenovirus (RCAs). The presence of RCAs in AdV preparations which are intended for use in humans is increasingly considered to be a potential risk, especially for immuno-compromised patients. The CAP(R) cell line is specifically designed for RCA-free production of AdV.

About CEVEC Pharmaceuticals GmbH

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale. The company's product portfolio comprises platform technologies for gene therapy viral vectors and complex recombinant proteins. With ELEVECTA(R) CEVEC has developed the first technology which stably incorporates all elements required for AAV production into the genome of one producer cell. CEVEC's CAP(R) Technology based on human suspension cells is the ideal production platform for RCA-free adenoviral vectors, viral vaccines and exosomes. With CAP(R) Go CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors, and plasma proteins.

For more information, please visit http://www.cevec.com and follow us on LinkedIn.

About CARISMA Therapeutics Inc.

CARISMA Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.

For more information, please visit http://www.carismatx.com.

CONTACT:

Continue reading here:
CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies - BioSpace

The United States Food and Drug Administration (FDA) has given the green light for experimental trials of a truly new therapy for Type 1 diabetes.

The new therapy, named VX-880, is referred to in a press release as an investigational stem cell-derived, fully differentiated pancreatic islet cell therapy to treat T1D. In plain English, VX-880 uses laboratory stem cells that have been grown into insulin-producing pancreatic beta cells. Those cells are then transplanted into a patient with Type 1 diabetes, and act just as the patients own beta cells should, hopefully restoring the bodys ability to sense glucose levels and secrete insulin in response.

Its an exciting moment for the treatment. Vertex, the business developing VX-880, has already run successful proof-of-concept animal testing. The therapy is ready for the next huge hurdle, tests in humans.

While diabetes technologies and therapies have improved at a rapid pace over recent decades, there has still be very little meaningful work done on reversing the root cause of diabetes: the autoimmune reaction that destroys the beta cells in the pancreas that secrete insulin. A therapy that could restore pancreatic function could potentially function as an actual cure, correcting the root dysfunction rather than just mitigating its effects.

For now, thats still a dream there is a very long road for the therapy to travel before we can realistically talk about it as an option for patients. People with diabetes can be understandably skeptical about potential cures, having heard about so many breakthroughs over the years that have thus far amounted to little or nothing. Only a thin minority of the drugs that begin Phase 1 clinical testing ever make it to the market. Even if it works, we dont yet know if VX-880 could wholly restore beta cell function, or only partially restore it, necessitating the continued use of some exogenous insulin.

While practical application may be a long way away, the therapy has already come pretty far to get to this point. Its genesis began years ago with the work of Dr. Douglas Melton of the Harvard Stem Cell Institute. Melton founded a company, Semma Therapeutics, to work on the therapy. Last year, Semma Therapeutics was acquired by a larger biotech firm, Vertex, for nearly $1 billion. Thats an eye-opening bet on the technology.

Dr. Melton is extremely optimistic about his breakthrough. In a 2019 interview, he stated, Im convinced that those cells will cure the disease.

Of course, even a Type 1 diabetes cure could come with strings attached. VX-880, for example, will require the chronic administration of concomitant immunosuppressive therapy in order to prevent the new islet cells from rejection by the bodys immune system. No word yet on how burdensome immunosuppressive therapy might be for patients. Vertex has also investigated other methods of protecting new islet cells from the immune system; another concept would implant new islet cells in a kind of porous tea bag that would allow both glucose and insulin to filter through, but block immune cells.

Initial trials will restrict VX-880 to some of the patients most in need of a radical therapy, those with hypo unawareness and a history of severe hypoglycemia. The company will recruit about 17 patients for the Phase 1 testing.

Go here to read the rest:
FDA Green Lights Trials of New Type 1 Diabetes Stem Cell Therapy - A Sweet Life

With the rising demand for cell and gene therapies, the need for manufacturing innovation has never been higher. A surge of deals and expansions in the last year is fuelling the push to truly make these therapies widely available and affordable.

Cell and gene therapies offer huge potential to treat a wide range of diseases including cancer, neurological, and genetic diseases. They have even shown promise to treat the symptoms of Covid-19.

The amount of academic and early-stage biotech research in this area has skyrocketed over the last few years. According to the Alliance for Regenerative Medicine, there are currently 1,220 ongoing clinical trials in this space, 152 of which are at phase III. Despite the global pandemic, investment in this area is also at a record high around the world, with the equivalent of 15.7B invested in 2020, a figure double that of 2019.

But research alone cannot get these complex treatments to patients. The sharp discrepancy between the high number of products in early-stage development and the still very small number that have made it onto the market, as well as their cost, speaks to the impact and importance of cost-effective and scalable manufacturing, Ryan Cawood, CEO of Oxgene (previously Oxford Genetics), told me. Oxgene is a UK biotech aiming to improve manufacturing for cell and gene therapies.

To meet this challenge, cell and gene therapy producers are exploding into motion. With 2021 only just getting started, weve seen manufacturing deals between Vigeneron and Daiichi Sankyo, Sirion Biotech and Cellectis, and Cevec and Biogen. The giant Thermo Fisher Scientific absorbed the Belgian viral vector producer Henogen for 724M. And CDMO heavyweights like Cognate BioServices and Polyplus Transfection have announced expansions to their manufacturing capacity.

Thedifficulties with manufacturing the recently approved Covid-19 mRNA vaccines in high enough quantities has really highlighted the importance of having a solid manufacturing strategy in place. This lesson applies equally to companies trying to take cell and gene therapies to market.

Stuck in the first generation

Despite the huge increase in development of cell and gene therapies over the past couple of years, manufacturing technology for these therapies is largely still at the first-generation stage. This can make scaling up a challenge.

Often cell and gene therapy manufacturing processes are highly manual stemming from the early academic or process development stage and, without adequate technology solutions available currently, these processes often remain this way through clinical trials and then into commercial manufacturing, said Jason Foster, CEO of Ori Biotech, a London- and New Jersey-based company focusing on cell and gene therapy manufacturing.

These first-generation processes cause manufacturing to be expensive, highly variable and low-throughput, which reduces the ability of patients to access these potentially life-saving therapies.

Another problem common to all bio-based therapeutics is that any product sourced from a live cell or a component of one is subject to a lot more variation than a simpler pharmaceutical product.

Most gene therapies are built on viruses found in nature. They have not evolved for very high productivity in a large-scale, animal component-free bioreactor, said Cawood.

The more complicated the biologic becomes, the more parts of it require optimization, and the more analytics you require.

According to Kevin Alessandri, the cofounder and CEO/CTO of the French company TreeFrog Therapeutics, there is also a lot of waste in cell therapy manufacturing.

Yields are impaired by high cell death at every passage, and genetic alterations inevitably arise, said Alessandri. When it comes to producing commercial batches to treat thousands of patients, scaling out 2D cell culture processes is far too expensive and poses batch-to-batch reproducibility issues.

While many in the industry are now turning to bioreactors to produce cells on a bigger scale, this is also not without problems. Impeller-induced shear stress is damaging the cells, thus negatively impacting cell viability and triggering undesired genetic mutations, explained Alessandri.

Taking manufacturing up a gear

What are companies in this space doing to make scaling up cell and gene therapies easier, quicker, and cheaper?

Ori Biotech raised24.8M in Series A funding in October last year to develop an automated and robotic manufacturing system to minimize the number of manual steps needed to produce a given cell or gene therapy. This speeds up the process as well as making it more accurate. Another advantage of the technology is that it can tailor the production capacity according to demand.

This is impossible to do in most current processes, which involve manual tube welding and transfers from flask to bag to bigger bag to bioreactor, said Foster, adding that this increases cost and variability while constraining throughput. Oris technology, in contrast, could take years off the production timeline and cut costs by as much as 80%.

London-based Synthace is one of several companies trying to improve advanced therapeutic manufacturing by developing software and computer systems to optimize the process, rather than industrial machinery.

Peter Crane, Corporate Strategy Manager for the company, said that in-depth data analysis and planning before starting the manufacturing process can make a big difference to outcomes, and that connected software can help make this task easier.

The best way to remove some of the risk associated with biomanufacturing of these products is to solve as many problems as possible before manufacturing.

In addition to making the process quicker, cheaper, and more accurate, computing tools can also help with quality control and tracking. In cell therapy manufacturing, especially autologous products, line of sight around electronic batch records, as well as the vein-to-vein supply chain, is incredibly important, emphasized Crane.

Another company specifically focusing on logistics and quality control is the Cardiff- and San Francisco-based TrakCel, which nailed deals with Ori Biotech in February and the UKs National Health Service in November.

The company TreeFrog Therapeutics works with cell encapsulation technology to improve quality and reduce waste, albeit from a more mechanical viewpoint. The company launched an industrial demonstration plant in June last year, followed by two co-development deals with undisclosed big pharma partners.

Encapsulated stem cells spontaneously self-organize in an in vivo-like 3D conformation promoting fast and homogeneous growth, as well as genomic stability, said Alessandri. The resulting 3D stem cell colony can then be differentiated in the capsule into functional microtissues ready for transplantation.

With our technology, which is based on high-throughput microfluidics capable of generating over 1,000 capsules per second, it becomes possible to expand and differentiate stem cells at a large scale, in industrial bioreactors, with best-in-class cell quality and reduced operating costs.

Oxgene has a focus on scaling up production for manufacturers. In September, the company launched a technology to scale up manufacturing of viral vector production with less contamination and a 40-fold improvement in yield compared to current methods. Oxgenes expertise with viral vectors also prompted a collaboration deal in April with the CDMO Fujifilm Diosynth Biotechnologies.

Innovation in new manufacturing technologies just hasnt kept pace with the level of discovery around genetic disease and potential avenues open to treat them, or even development of the viral vectors themselves, said Cawood. This is definitely changing though.

Enter the second generation of manufacturing

Cell and gene therapy manufacturing is definitely hot right now, boosted by increased needs from biotech and pharma companies developing Covid-19 vaccines and therapies, and by notable increases in investment.

Huge advances in gene and cell therapies over the last few years, such as the approval of the eye gene therapy Luxturna and the first CAR T-cell therapies, mean the demand for new manufacturing technologies has also increased exponentially.

A lot of very promising programs are now in the pipeline, and patients are waiting for their approval, said Alessandri. Industry urgently needs robust manufacturing technology, capable of serving millions of patients.

European biotechs are busy developing second-generation technologies to allow easier and cheaper scale up, producing higher quality products with less waste. They could start to phase out first-generation methods very soon.

The realm of cell manufacturing in industrial and food biotech is also likely to see big breakthroughs in the coming years. Earlier this month, for instance, the nutrition and health giant Royal DSM set up a lab in the Netherlands dedicated to applying artificial intelligence (AI) to the challenge of growing microbial strains at a commercial scale.

Rapid improvements in advanced computing options such as AI and machine learning technology, as well as robotics, are already having an effect on the industry, but this will only get bigger as time goes on.

Cover image from Elena Resko. Body text image from Shutterstock

Go here to see the original:
Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu

Vancouver, British Columbia, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell Therapeutics will be the Key Factor Driving the Industry Growth, States Emergen Research

The global stem cell therapy market size was valued at USD 342.7 Million in 2019 and is anticipated to reach USD 3,693.6 Million by 2027 at a CAGR of 36.2%, over the forecast period, according to most recent analysis by Emergen Research.

Growing prevalence of chronic diseases will drive the growth of the stem cell therapy market. Increased investment in research activities, development of advanced genetic techniques, and rise in public-private partnership will contribute to the growth of the stem cell therapy market.

Stem cells are used to improve health and manage disease. The growing popularity of regenerative medicine has encouraged the growth of stem cell therapy market. Regenerative medicines are used to replace, repair, and regenerate tissues affected by disease, injury, and aging process. Regenerative medicines are used in research to find a cure for diabetes, Parkinson's, and Alzheimer's disease.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample-form/83

However, ethical concerns regarding embryonic stem cells and less developed research infrastructure will hinder the stem cell therapy market's growth.

Companies Profiled in Stem Cell Therapy Market Research Report:

Virgin Health Bank, Celgene Corporation, ReNeuron Group plc, Biovault Family, Precious Cells International Ltd., Mesoblast Ltd., Opexa Therapeutics, Inc., Caladrius, Neuralstem, Inc., and Pluristem.

Key Highlights of Report

Check Our Prices@ https://www.emergenresearch.com/select-license/83Emergen Research has segmented the global stem cell therapy market in terms of type, application, end-users, and region:

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/stem-cell-therapy-market

Take a Look at our Related Reports:

AI-Enabled Medical Imaging Solutions Market By Product (Software, Hardware), By Workflow (Image Acquisition, Image Analysis, Reporting, and Communication), By Therapeutic Application (General Imaging, Specialty Imaging), By Deployment Mode, By Modality, and By Region, Forecasts to 2027

Patient Registry Software Market By Delivery, By Database, By Registry Type, By Function, By Software Type (Integrated, Standalone), By End-use (Government & Third-Party Administrators, Pharmaceutical Companies, Hospitals, Research Centers, Others), and By Region, Forecast to 2027

Operating Room Management Solutions Market By Solution Type (Data management and communication solutions, Operating room supply management solutions, Anesthesia information management solutions, Operating room scheduling solutions, Performance management solutions), By Mode of Deployment (Ob-premises, Cloud-based), By End-Use (Hospitals, Ambulatory surgical centers), and By Region

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: http://www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.emergenresearch.com/press-release/global-stem-cell-therapy-market

Read this article:
Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell...

CHICAGO, Feb. 2, 2021 /PRNewswire/ -- Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced the launch of CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye.

"The addition of CiRC Biosciences to our portfolio builds upon our cell and gene therapy platform, an area that has tremendous potential to address serious genetic diseases," said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. "CiRC Biosciences gives us the science to target retinal diseases that could lead to vision restoration with numerous other applications in the years ahead."

CiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness. There are no U.S. Food & Drug Administration (FDA) approved treatments to restore vision loss in Dry AMD or RP.

The company's novel mechanism of action is designed for direct chemical conversion of fibroblasts into other cell types using a cocktail of small molecules in an 11-day chemical conversion process. Pre-clinical studies have shown efficacy in blind mice that demonstrated vision restoration. CiRC Biosciences has provisional patent applications to protect its platform.

"Our technology transforms ordinary skin cells into specialized retinal cells using a cocktail of small molecules," said Sai Chavala, M.D., co-founder and chief scientific officer of CiRC Biosciences. "This process is potentially safer, quicker, more cost effective and easier to manufacturer than using traditional stem cells. Working with Paragon Biosciences to build and advance CiRC Biosciences provides us the opportunity to efficiently progress this technology through research and development stages.

CiRC Biosciences first reported its discovery in the highly respected scientific journal Nature (April 15, 2020). A recently published New England Journal of Medicine article (Nov. 5, 2020)discussed CiRC's technology of using chemically induced cells to restore retinal function. The article concluded, "The new and emerging strategies for the rescue, regeneration, and replacement of photoreceptors suggest a bright future in the fight to preserve and restore vision in blinding eye diseases."

The abstract in Nature is available here: https://www.nature.com/articles/s41586-020-2201-4

Access to the NEJM article is available here: https://www.nejm.org/doi/full/10.1056/NEJMcibr2027602

About CiRC Biosciences CiRC Biosciences is a privately held cell therapy company dedicated to developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Currently it is pre-clinical phase for Geographic Atrophy Age-Related Macular Degeneration (Dry AMD) and advanced Retinitis Pigmentosa (RP). CiRC Biosciences is a portfolio company of Paragon Biosciences. Visit our website: https://circbiosciences.com/.

About Paragon Biosciences Paragon is a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence. The company's current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com/.

Media Contact:

Evelyn M. O'Connor Paragon Biosciences 312-847-1335 [emailprotected]

SOURCE Paragon Biosciences

Paragon Biosciences: Accelerating Life Science Innovation

Go here to read the rest:
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform - PRNewswire

SAN DIEGO (PRWEB) January 29, 2021

ProgenCell Stem Cell Therapies announced an updated stem cell therapy for anti aging or healthy aging protocol. A Comprehensive protocol developed by the more than 12 years of experience in the field of Regenerative Medicine and the most rigorous scientific protocols, and overseen by an Independent Review Board (IRB) composed by prominent figures in medicine and scientific research.

The Anti Aging Stem Cell Treatment Protocol is performed administering stem cells intravenously with a previous and strict regimen of multivitamins, minerals and hormones and a subsequent nutritional and vitamin support.

This updated protocol has been developed thanks to the information we have been able to compile, analyze and research, allowing us to determine the dosage of the vitamins. Hormones and nutrients administered according to each patients context, added Dr. Jorge Luis Gavio ProgenCells Medical Director. ProgenCells stem cell research center has an in-house laboratory and adjacent medical facility, which not only sets us apart as an institution, it also gives us the scientific platform to upgrade our protocols, he continued.

To date, ProgenCell Stem Cell Therapies has been offering stem cell therapy in Mexico successfully with a wide range of protocolos designed specifically for many conditions including Parkinsons Disease, Multiple Sclerosis, Retinitis Pigmentosa, and arthritis just to name a few.

Stem cell therapy for anti aging at ProgenCell Stem Cell Therapies is offered by board certified and fully licensed doctors, and every case is overseed by an Independent Review Board, with a scientific and Ethics Committee.

The treatments at ProgenCell Stem Cells comply with quality assurance standards that exceed those recommended by the FDA (Federal Drug Administration), and all protocols are registered and audited by COFEPRIS (the mexican government agency with jurisdiction).

The process of becoming a ProgenCell Patient for Anti Aging Stem Cell Therapy Protocol starts with a free virtual consultation with a Regenerative Medicine Scientific Liaison who will guide you through the process and establish a health route map. After the treatment is booked, a patient concierge works with each international patient on travel logistics, to live the full ProgenCel Experience.

For more information on stem cell therapy for anti aging and to obtain a free consultation, call (888) 443-6235 or visit http://www.progencell.com to learn more.

Share article on social media or email:

View post:
ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web

Global CAR T Cell Therapy Market Report Provides Significant Market Growth Analysis

The globalCAR T Cell Therapy marketreport delivers a complete and in-detail study of the market using primary or secondary resource and various research tools. The market weakness, opportunities, strength, and risk analysis provide holistic picture of the market growth and development. Moreover, the CAR T Cell Therapy report includes company profiles ofCellectis, Juno Therapeutics, Pfizer, Inc., Celgene Corporation, Novartis International AG, Kite Pharma, Inc., Bellicum Pharmaceuticals, Inc.that detail product analysis, financial structure, business strategies, sales, and revenue of the market.

To know How COVID-19 Pandemic Will Impact This CAR T Cell Therapy Market| Download PDF Sample copy of the Report@https://www.marketresearchstore.com/report/global-car-t-cell-therapy-industry-market-report-690461#RequestSample

The financial structure of the industry is well comprehended in the report through the supply and demand and costing analysis of the CAR T Cell Therapy market. A wide-range analysis of the CAR T Cell Therapy market touches upon several market segmentation, dynamics, growth stimulators, and geographical distribution.

This market research report provides a complete overview of theCAR T Cell Therapy market. Likewise, the regional expansion of the CAR T Cell Therapy help implement various business strategies, market status, and revenue growth in the global market. The regions North & South America (United States, Mexico, Canada, Brazil, Argentina, Chile, etc.), Europe (Italy, Germany, Russia, UK, Turkey, France, etc.), The Middle East and Africa (South Africa, Sudan, GCC Countries, Egypt, etc.), Asia-Pacific (China, Malaysia, Japan, Vietnam, Singapore, Korea, India, Indonesia, and Australia) explain the product consumption, latest product developments, technological innovations, and industry policies implemented for enhancing the market growth.

The report provides all the market growth and key facet evaluations of the CAR T Cell Therapy market. Furthermore, the market volume, size, and share data provided in the report help clients make wise choices before investing in the CAR T Cell Therapy industry.

Other substantial factors of the CAR T Cell Therapy market include market future scope and latest trends to overcome theCOVID-19 impacton the market growth. This report delivers data associated with industry share and growth contributors.

Key aspects of the global CAR T Cell Therapy market:

Theoretical, graphical, bar & pie chart analysis of the global CAR T Cell Therapy market provides details such as growth, products, and other segmented study Latest and future market trends of CAR T Cell Therapy industry delivered in the report provides better investment, pricing, and expansion opportunity details Major business strategies and industry trends of the CAR T Cell Therapy market are provided Competitive dynamics and regional segmentation delivers pin-point and comprehensive analysis of the global CAR T Cell Therapy market growth Drivers, restraints, opportunities, and other trends of the CAR T Cell Therapy market are provided

CAR T Cell Therapy Market, By Product (2020-2026)

CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll

CAR T Cell Therapy Market, By Application/End-use (2020-2026)

Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert::https://www.marketresearchstore.com/report/global-car-t-cell-therapy-industry-market-report-690461#InquiryForBuying

Key Reasons for Purchasing Global CAR T Cell Therapy Market Report:

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities Key competitive players and regional distribution will help find prospective market analytics Report will strengthen the investors decision-making processes

Read more here:
Global CAR T Cell Therapy Market Size to Grow with Stupendous CAGR | Key Driver and Growth Forecasts 2026 The Courier - The Courier

Industry and Researchhave published a [100+ Pages] new research report titled CAR T-Cell TherapyMarket By Type ((Monotherapy, Combination Therapy)), By Application ((Multiple Myeloma, Refractory or Relapsed Multiple Myeloma)), and By Region: Global Industry Outlook, Market Size, Historical Developments, Current Trends, and Forecasts, 20202026. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The global CAR T-Cell Therapy market has been deeply evaluated in the report covering scope, profitability, demand status, uncertainties, and development forecast. The report analyzes the historical and current pace of the market development and other occurrences and offers detailed and accurate estimates up to 2026. The report help market players to penetrate market events, figures, and analysis at a minute level and navigate their businesses accordingly. The report also incorporates a significant evaluation of market share, size, demand, production volume, sales revenue, and annual growth rates. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts. The report offers a brief overview of this industry landscape including insights pertaining to growth factors, limitations, opportunities and other future prospects influencing the business scenario. This report focuses on the key global CAR T-Cell Therapy players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

Competitors identified in this market include, among others:Juno Therapeutics, Kite Pharma, Novartis, Collectis, , ,

{Company Profiles, Revenues, Profile and SWOT analysis}

Request Your Free Sample Report of CAR T-Cell Therapy Market (The free sample of this report is readily available on request) @https://www.industryandresearch.com/report/Global-CAR-T-Cell-Therapy-Market-Growth-In-depth-InsightKey-Research-Finding-to-20202026/218241#samplereport

The Global CAR T-Cell Therapy Market report offers a complete analysis of the CAR T-Cell Therapy market size in addition to CAGR for the estimated period of 20202026. The CAR T-Cell Therapy report illustrates the correct profit initialization with various CAR T-Cell Therapy market sections. This report also demonstrates the investment outline for the CAR T-Cell Therapy market. Furthermore, the CAR T-Cell Therapy market report entails important data related to new products launched in the market, various approvals, domestic scenarios and as well the company tactics adopted in the ambitious CAR T-Cell Therapy market. The CAR T-Cell Therapy market is examined based on the pricing of the products, the dynamics of demand and supply, total volume produced, and the revenue produced by the products. The manufacturing is studied with respect to different contributors such as manufacturing plant distribution, industry production, capacity, research, and development. The global CAR T-Cell Therapy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading CAR T-Cell Therapy market players and offers key trends and opportunities in the market. For any new establishment or new startup different approaches are listed to expand the businesses rapidly. Communally, this research report focus on numerous stakeholders, clients, and companies in the businesses. A major chunk of this research report talks about the technological advancements and platforms that are and will influence the progress of global.

The CAR T-Cell Therapy market report provides a comprehensive scope of the market which includes future supply and demand scenarios, changing market trends, high growth opportunities, and in-depth analysis of the future market prospects. The report features real-time developments in the global CAR T-Cell Therapy market encompasses a highly structured and comprehensive outlook of the market. It shows market types and applications that are categorized as ideal market segments. The report covers the competitive data analysis of the emerging and prominent players of the market. Along with this, it provides comprehensive data analysis on the risk factors, challenges, and possible new market avenues. The trends affecting the Industry in emerging regional sectors have additionally been explained in this study. The current findings and recommendations the analysts suggest for the future growth of the market have also been evaluated in this Mainframe Security report. To make the report more potent and easy to understand, it consists of infographics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Geographical Segments:The primary geographical areas North America(U.S., Canada, Rest of North America), Europe(UK, Germany, France, Italy, Spain, Rest of Europe), Asia Pacific(China, Japan, India, Southeast Asia, Rest of Asia Pacific), Latin America (Brazil, Argentina, Rest of Latin America), Middle East and Africa(GCC Countries, South Africa, Rest of Middle East & Africa) are also examined in this report. The report also contains graphs, realistic figures, and diagrams, which show the status of the Investigative Analytics market on the regional and global platforms.

The CAR T-Cell Therapy Market research gets rid of the following queries:* How the market for CAR T-Cell Therapy Market is expected to shape in the coming ten years?* What strategies are the CAR T-Cell Therapy Market vendors implementing to stay ahead of their rivals?* Why are consumers shifting towards alternative CAR T-Cell Therapy Market products?* What innovative technologies are the CAR T-Cell Therapy Market players using to get an edge over their rivals?* What are the restraints affecting the growth of the CAR T-Cell Therapy Market?

Reasons for Buying CAR T-Cell Therapy market* This report provides pin-point analysis for changing competitive dynamics* It provides a forward looking perspective on different factors driving or restraining market growth* It provides a six-year forecast assessed on the basis of how the market is predicted to grow* It helps in understanding the key product segments and their future* It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors* It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Read Detailed Index Report @https://www.industryandresearch.com/report/Global-CAR-T-Cell-Therapy-Market-Growth-In-depth-InsightKey-Research-Finding-to-20202026/218241

The global CAR T-Cell Therapy market report is an extensive industry study of manufacture analysis, growth factors, supply, share, current market demand, demands, forecast trends, limitations, size, sales, and production. It includes the study of new innovation improvements, extensive profiles of the most important competitors, and a business model study. It also contains well-defined market estimates for the upcoming years. The latest developmental trends and future market prospects that are likely to spearhead current product demand and future status of this market are elaborately comprehended. The basic approach of our report is to provide answers to all the CAR T-Cell Therapy market-related questions for future decision-making. Further, to validate and speed up the data collection process, our analysts have used primary & secondary resources along with few of the accurate market analysis tools.

In conclusion, this report covers the descriptive outline of the parent CAR T-Cell Therapy market supported key players, current and the historical information which will give benefit to all the CAR T-Cell Therapy business competitors. In short, CAR T-Cell Therapy research report gives crucial and necessary ideas of major key vendors, with company profiles of the vendors, past and the present market outlook which would help coming markets to make the good position in the market.

If you have any special needs, please let us know (sales@industryandresearch.com) and we will offer you the report as you want.

Read the rest here:
Global CAR T-Cell Therapy Market Insights, Status and Forecast 2021-2026 | Juno Therapeutics, Kite Pharma, Novartis, Collectis KSU | The Sentinel...

Stem Cell Therapy Market is valued at USD 9.32 Billion in 2018 and expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% over the forecast period.

Rising prevalence of chronic diseases, increasing spend on research & development and increasing collaboration between industry and academia driving the growth of stem cell therapy market.

Scope of Stem Cell Therapy Market-

Stem cells therapy also known as regenerative medicine therapy, stem-cell therapy is the use of stem cells to prevent or treat the condition or disease. Stem cell are the special type of cells those differentiated from other type of cell into two defining characteristics including the ability to differentiate into a specialized adult cell type and perpetual self-renewal. Under the appropriate conditions in the body or a laboratory stem cells are capable to build every tissue called daughter cells in the human body; hence these cells have great potential for future therapeutic uses in tissue regeneration and repair. Among stem cell pluripotent are the type of cell that can become any cell in the adult body, and multipotent type of cell are restricted to becoming a more limited population of cells.

Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/1246

The stem cell therapy has been used to treat people with conditions including leukemia and lymphoma, however this is the only form of stem-cell therapy which is widely practiced. Prochymal are another stem-cell therapy was conditionally approved in Canada in 2012 for the treatment of acute graft-vs-host disease in children those are not responding to steroids. Nevertheless, hematopoietic stem cell transplantation is the only established therapy using stem cells. This therapy involves the bone marrow transplantation.

Stem cell therapy market report is segmented based on type, therapeutic application, cell source and by regional & country level. Based upon type, stem cell therapy market is classified into allogeneic stem cell therapy market and autologous market.

Stem Cell Therapy Companies:

Stem cell therapy market report covers prominent players like,

Based upon therapeutic application, stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications. Based upon cell source, stem cell therapy market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells and other cell sources

The regions covered in this stem cell therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of stem cell therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Stem Cell Therapy Market Segmentation

By Type

Allogeneic Stem Cell Therapy Market, By Application

Autologous Market, By Application

By Therapeutic Application

By Cell Source

Stem Cell Therapy Market Dynamics

Rising spend on research and development activities in the research institutes and biotech industries driving the growth of the stem cell therapy market during the forecast period. For instance, in January 2010, U. S. based Augusta University initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsy in children. The study is estimated to complete in July 2020. Additionally, increasing prevalence of chronic diseases creating the demand of stem cell therapy. For instance, as per the international diabetes federation, in 2019, around 463 million population across the world were living with diabetes; by 2045 it is expected to rise around 700 million. Among all 79% of population with diabetes were living in low- and middle-income countries. These all factors are fuelling the growth of market over the forecast period. On the other flip, probabilities of getting success is less in the therapeutics by stem cell may restrain the growth of market. Nevertheless, Advancement of technologies and government initiative to encourage research in stem cell therapy expected to create lucrative opportunity in stem cell therapy market over the forecast period.

Stem Cell Therapy Market Regional Analysis

North America is dominating the stem cell therapy market due increasing adoption rate of novel stem cell therapies fueling the growth of market in the region. Additionally, favorable government initiatives have encouraging the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program, in which gov will invests in research activities carried out for stem cell therapies. In addition, good reimbursing scheme in the region helping patient to spend more on health. Above mentioned factors are expected to drive the North America over the forecast period.

Full Research Report @ https://brandessenceresearch.com/healthcare/stem-cell-therapy-market-size

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact usat: +44-2038074155 ormail usatsales@brandessenceresearch.com

Website: https://brandessenceresearch.com/

Article: https://businessstatsnews.com

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog: https://industrywatchnews.com/

See the rest here:
Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |...